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1. Introduction 
Venous Thromboembolism (VTE) is a major complication of cancer and is one of the leading 
causes of death in patients with cancer. The risk for VTE in this group of patients is 
increased several folds in hospitalized cancer patient and in those on active therapy. The 
short and long term consequences of VTE diagnosis in cancer patients are many including 
increased in mortality rate, bleeding while on therapy for VTE.  It has, therefore, become 
important to identify the risk factors for cancer-associated VTE, develop guidelines for 
prevention strategies for high-risk patients as well as management of VTE when it 
complicates the course of cancer disease or its treatment with chemotherapy 
immunomodulatory agents, antiangiogenesis or hormonal therapy. Proper understanding 
of the epidemiology and pathophysiology of VTE and its risk factors in cancer patients is 
central to adequate prevention and management of this serious complication in cancer 
patients.     
2. The epidemiology and pathophysiology of venous thrombosis in cancer 
patients  
2.1 Cancer cells and the haemostatic mechanisms 
The haemostatic system is a complex, multifaceted mechanism that participates in 
maintaining the integrity of the vascular system and fluidity of blood. In coordination with 
the mechanisms of inflammation and repair, the haemostatic mechanism produces a 
coordinated response. Haemostatic systems are normally quiescent and are only activated 
after injury and results in the production of a platelet plug, fibrin-based clot, deposition of 
white cells at the site of injury, and activation of inflammatory and repair processes. 
Tumor cells can activate blood coagulation through multiple mechanisms, including (a) 
production of procoagulant, fibrinolytic, and proaggregating activities; (b) release of 
proinflammatory and proangiogenic cytokines and (c) direct interaction with host vascular 
and blood cells through adhesion molecules.  
Miller et al (1) studied the link between the haemostatic systems and cancer where the 
authors evaluated haemostatic status every year for 4 years in a population of 
approximately 3000 middle-aged men without cancer. Among patients with the activation 
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of the haemostatic system (defined as persistent elevation of fibrinopeptide A and 
prothrombin fragment 1+2 levels), total mortality was significantly higher in participants 
with persistent activation (17.1/1000 person-years) than in patients without activation 
(9.7/1000 person-years; p=0.015). This difference was attributed to an increased incidence of 
death from cancers (11.3/1000 vs. 5.1/1000 person-years). 
The majority of patients with cancer has increased levels of procoagualnt factors V, VIII, IX, 
and XI, as well as increased levels of markers of coagulation activation (e.g., thrombin–
antithrombin, prothrombin fragment 1+2, fibrinopeptide and D-dimer (2). In addition, 
patients with some disseminated malignancies seem to have a deficient activity of von 
Willebrand's factor-cleaving protease (ADAMTS-13), resulting in unusually large von 
Willebrand factor multimers leading to platelet thrombosis (3). 
Many tumors have been shown to activate blood coagulation through an abnormal 
expression of high levels of the procoagulant molecule tissue factor (TF). In normal vascular 
cells, expression of TF is not expressed, except when induced by inflammatory cytokines 
such as interleukin 1┚ and tumor necrosis factor ┙ (TNF-┙) or by bacterial 
lipopolysaccharides. In tumor cells, TF is expressed and causes activation of the extrinsic 
pathway. In the elegant study conducted by Kakkar et al (4) plasma levels of TF, factor VIIa, 
factor XIIa, the thrombin–antithrombin complex, and prothrombin fragments were elevated 
in patients with cancer compared with healthy controls. Tissue factor and factor VIIa levels 
were both significantly higher, suggesting significant activation of the extrinsic pathway.  
On the other hand, levels of factor XIIa were only marginally elevated, indicating that the 
intrinsic pathway is not involved to a significant degree in the hypercoagulable state seen in 
patients with cancer (5). 
Tumor cells express cancer procoagulant, a cysteine protease expressed only on malignant 
tissues. Cancer procoagulant directly activates factor X in the common pathway 
independent of factor VII (6). The activity of this protease seems to be driven by the stage of 
cancer.  The onset of cancer is usually associated with high levels of protease slowly declines 
thereafter (7), partially explaining the tendency of thromboembolic events to occur during 
the first three month following the diagnosis of cancer. 
In addition to the expression of TF and cancer procoagulant, tumor cells enhance 
coagulation in patients with cancer by expressing proteins that regulate the fibrinolytic 
system, including plasminogen activators, plasminogen activator inhibitors 1 and 2, and 
plasminogen-activator receptor, leading to an imbalance of fibrinolytic mechanism (8) 
Tumor cells may elicit platelet activation and aggregation through direct cell–cell 
interactions or through the release of soluble mediators, including ADP, thrombin, and 
other proteases. Furthermore, expression of certain cytokines by tumor cells, including TNF-
┙ and interleukin 1┚, induces expression of TF on endothelial cells and simultaneously 
downregulates the expression of thrombomodulin, resulting in a prothrombotic state at the 
vascular wall.Multiple studies have provided considerable evidence for a bidirectional 
clinical association between VTE and cancer, in that cancer elicits expression of 
procoagulant activities, contributing to the prothrombotic state in these patients, and the 
procoagulant activities themselves seem to elicit cancer growth, proliferation, and 
metastasis. Fibrin and platelet deposition around solid tumor cells promotes angiogenesis 
through platelet-derived proangiogenic factors, and may seal immature tumor vasculature 
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and provide a degree of protection to the cancer cells from the immune system. Fibrin has 
also been shown to increase expression of TF and induce expression of IL-8 and vascular 
endothelium growth factor (VEGF) and thereby, enhancing angiogenesis (9-10). 
The TF–factor VIIa complex can signal through cleavage of protease-activated receptors, 
which, in turn, induce the mitogen-activated protein kinase (MAPK) signal transduction 
cascade (11). The MAPK pathway is involved in the induction of genes involved in 
angiogenesis, migration, and proliferation. In addition, phosphorylation of the cytoplasmic 
tail of the TF receptor has also been shown to indirectly activate transcription of VEGF, 
downregulate thrombospondin (an antiangiogenic protein), and induce cell migration. 
Expression of TF by malignant cells also seems to support metastatic process and is 
dependent on the formation of the TF-factor VIIa complex (11). 
2.2 The incidence of venous thromboembolism in cancer patients 
The first description of deep vein thrombosis (DVT) in patients with cancer was made by 
Bouillard in 1823(12) although this was popularly first credited to Armand Troussean, the 
French Physician, in 1865 (13-14).   Since that time, hundreds of studies have provided solid 
data on the clinical association between VTE and cancer, and delineated the elevated risk for 
VTE particularly during the first few months following the diagnosis of cancer and in the 
presence of distant metastasis (15-18). 
The incidence of DVT or PE in patients with cancer varies widely because of the heterogeneity 
of the patients’ population and the difficulty of conducting large epidemiological studies. 
Based on a prospective medical database in the United States, the annual incidence of a first 
episode of DVT or PE in the general population is 0.1% (15), while the estimated annual 
incidence of VTE in the cancer population is 0.5%. (19-21) The prevalence of cancer-associated 
thrombosis may be underestimated by more than 10-fold as autopsy studies in cancer patients 
have demonstrated even higher rates of VTE (17-22). In a large population-based 
epidemiological study, approximately 20% of all new cases of VTE are associated with 
underlying cancer, whereas 26% of incident cases had idiopathic VTE (15). 
The risk of VTE associated with different malignancies has more recently been quantified in 
NHL (23), colonic cancer (24) ovarian (25) lung (26) and breast cancer (27). It was generally 
thought that solid tumors, such as pancreatic, ovarian and brain cancer carry a much higher 
risk for VTE than haematological malignancies. However, recent studies suggest that the 
incidence of VTE in patients with haematological malignancies may be similar to that 
observed in patients with solid tumors (28). In a population based case-control study of 
patients with a first episode of VTE, Blom et al found that the odds ratio of developing VTE 
among patients with haematological malignancies was approximately 26 compared to the 
general population (18).  Similar results were also reported by other authors (29-31).   
Prospective studies has shown that VTE have inflicted a higher risk of several adverse 
complications on patients with cancer including recurrent VTE, bleeding complications 
while on anticoagulant treatment, increase in both short-term and long-term mortality (32-
33) and increased mortality during first 3 month of therapy. The risk of VTE is markedly 
different for cancer patients throughout the course of the disease and this variable incidence 
of VTE comorbidity in cancer patients can be attributed to a combination risk factors related 
to the patient, the cancer itself and treatment (34).   
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2.3 Patient-related factors and risk of VTE 
a. Age: Older age has been shown to be associated with VTE in hospitalized cancer 
patients, but not in ambulatory patients (35-37). The rate of VTE in patients older than 
60 years of age undergoing surgery for various solid tumors was significantly higher 
than that in younger patients by multivariate analysis (OR 2.6) (36-38).  
b. Gender: Among cancer patients, most studies have identified male gender as a 
significant predictor of VTE. (19-20) However, A recent pooled retrospective study of 
VTE rates in a large cohort of hospitalized cancer patients reported a higher rate in 
females (OR 1.1, p < 0.0001) (39) 
c. Race: In the general population, the incidence of VTE varies by race.  In the USA, it is 
highest among blacks and lowest among Asian-Pacific Islanders (40). 
d. Previous thrombotic episode:  Cancer patients with a past history of VTE have a 6–7 
fold increased risk of developing VTE compared to those with no history of VTE (38). 
e. Obesity has been confirmed to be an important risk factor in cancer-associated 
thrombosis. Body mass index ≥35 kg/m2 was identified as one of five variables in a risk 
prediction model proposed by Khorana et al with an OR of 2.1 (38) 
f. Chronic co-morbid Medical Conditions: The presence of chronic medical co-morbid 
conditions such as chronic renal disease, chronic liver disease, hypertension and chronic 
heart failure has a marked effect on the incidence of cancer-associated thrombosis and 
survival.  The presence of three or more chronic medical conditions was the strongest 
risk factor for development of VTE among the patients with gliomas and ovarian 
cancer, and was the second strongest risk factor among patients with breast or colon 
cancer (39-40).  
2.4 Cancer-related factors to incidence of VTE   
a. Tumor type: certain tumors are strongly associated with VTE. In the retrospective 
cohort study of hospitalized cancer patients.  Khorana et al (38),  reported that sites of 
cancer with the highest proportion of patients with VTE were pancreas, brain and 
endometrial or cervical were 12.1%, 9.5% and 9%, respectively (California Cancer 
Registry). The incidence of VTE in pancreatic cancer patients is at least 10-fold higher 
than the rate in patients with prostate cancer. Histological subtype also predicts the 
increased risk of VTE in some types of malignancy. The incidence of VTE in patients 
with non-small cell lung cancer was 9.9% in patients with adenocarcinoma subtype 
versus 7.7% in patients with squamous cell carcinoma (HR 1.9, CI 1.7–2.1) (27, 26). 
Although mucin production was once proposed as the common feature and the 
thrombogenic mechanism amongst these mucin-producing tumors, the exact 
pathogenesis of the prothrombotic state of mucin is still not fully understood.  
b. Initial cancer stage: Patients diagnosed with local-stage cancer, in general, have a very 
low incidence of VTE, whereas the incidence is much higher in patients diagnosed with 
metastatic disease at time of diagnosis (24-27). 
c. Biological aggressiveness of cancer: The observed differences in the incidence of VTE 
between different cancer types correlate with the biological behavior of the cancer. A 
very strong correlation was found between the 1- year fatality rate and the 1-year 
cumulative incidence of VTE (41). In addition, presence of metastatic disease at the time 
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of diagnosis is a strong independent risk factor for developing VTE within the first year 
of cancer diagnosis (42-43).  
d. Rate of metastatic spread: The incidence of VTE has been reported to correlate with the 
rate of growth and spread of the cancer cells. Fast growing cancer such as colonic and 
ovarian, has been associated with a higher rate of VTE (24-25, 41-42) and patients with 
advanced and metastatic disease had a higher risk of VTE (OR 19.8, CI 2.6–149). The 
observed incidence of VTE in ovarian, colorectal, pancreatic, lung and breast cancer 
supports the finding that advanced stage increases the risk of cancer associated VTE 
(24-25, 44).  
2.5 Cancer Treatment-related factors and risk of VTE 
2.5.1  
Chemotherapy is one of the most important treatment-related factors in the aetiology of 
cancer-associated VTE as cancer alone is associated with a four-fold risk of thrombosis, 
while chemotherapy increases the risk by six-fold (45-47)  
Several different mechanisms have been reported to explain the prothrombotic states 
induced by chemotherapy including (a) damage to the vascular endothelium (48-49), (b) 
reduction of endogenous, physiological, anticoagulant factors (56-59), (c) increase of levels 
of procoagulants (54-57), (d) induction of tumor and endothelial level apoptosis and 
cytokine release that, in turn, lead to increased expression and hence activity of TF (56-57), 
(e) induction of platelet activation (58) and (f) direct induction of expression of monocyte-
macrophages TF (59).  
The following chemotherapeutic agents are associated with high risk for VTE: 
• Cisplatin based regimens 
Weiji et al (60), in a retrospective review of VTE in germ cell cancer patients treated with 
cisplatin and bleomycin-based chemotherapy reported an estimated risk of thrombosis of 
8.4%.  In a prospective study of VTE in non-small cell lung cancer patients treated with 
cisplatin and gemcitabine, Numico et al (61) reported VTE incidence of 17.6%. 
The mechanisms by which cisplatin induces thrombosis is not well known but in vitro 
studies suggest increase in the level of TF (48), platelet activation (50) and increased levels of 
von Willebrand factor suggesting endothelial injury (58). The latter perhaps explain the 
cisplatin induced arterial thrombosis.  Moore et al (62) conducted a large retrospective 
analysis to determine the incidence of venous and arterial thromboembolic events in 
patients treated with cisplatin-based chemotherapy and confirmed the unacceptable 
incidence of those events and recommend randomized studies to examine the question of 
prophylactic anticoagulation in patients with cancer treated with chemotherapy. 
• L-Asparaginase 
L-Asparaginase (ASNase) has been a mainstay in the treatment of paediatric patients with 
acute lymphoblastic leukemia since the 1960’s and there are several reports of ASNase 
containing regimen used in the treatment of paediatric ALL achieving a higher survival rate 
than non-ASNase treatment regimens used for ALL in adults and adolescents (63-65). 
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L-Asparaginase converts L-Asparagine to L-aspartic acid and, thereby, reduces levels of L-
Asparagine, an essential amino acid for protein synthesis and as a result, leukemic cell growth 
is inhibited.  However, the production of multiple plasma proteins by the liver including 
haemostatic factors, is also reduced and hence causing marked disruption of the haemostatic 
mechanism: prolongation of PT and aPTT, reduced fibrinogen level, reduced levels of protein 
C and protein S, Antithrombin III (AT) , plasminogen, factor IX and factor XII.  On the other 
hand, ASNase causes increased procoagulant factors V, VIII (54-56).  In addition, to the 
profound effects of the drug on the pro- and anticoagulant molecules, ASNase has also been 
shown to increase levels of immunomodulin a marker of vascular injury (66). 
The simultaneous effects of ASNase on both procoagulant and thrombolytic proteins 
increase the risk of both bleeding and thrombosis, the latter being the main challenge. 
The incidence of ASNase – associated VTE complications is age-dependent, 3-5% in children 
(67, 31) whereas the incidence reported from Dana-Farber Cancer Institute (1991-2008) in 
adult patients (≥ 30 years) was 34% and 42% (68).  Less intensive ASNase regimen in adult 
patients have reported lower rates of thrombotic complications (69).  Limited reports and 
data on a small number of patients treated with pegASNase –related DVT may be less 
frequent than those treated with after E. Coli ASNase (70-74).  In UKALL 2003, Children 
with DVT were routinely retreated with pegASNase and concurrent heparin prophylaxis 
without recurrence of thrombosis (75).  The confounding factors for VTE during ASNase 
therapy are presence of indwelling catheter, oral contraception, prednisolone and inherited 
thrombophilia (76). 
The majority of clinically important thrombotic events were those related to venous 
catheters and those in the central nervous system.  The majority of catheter-associated 
thrombosis (CAT) are asymptomatic and the majority, in both children and adults, occur 
during induction (68). 
In the randomized trial of native ASNase versus pegASNase (74), the incidence of cerebral 
venous sinus thrombosis (CVST) of 2-3% in children was reported.  In children ≥ 10 years, 
initial WBC > 50x109 /L at diagnosis may predict higher risk for CVST (77).  The GIMEMA 
study on adult ALL patients protocol, including E. Coli ASNase in the induction phase, CNS 
thrombotic events was 3% (77). 
Prevention and Management of ASNase induced thrombosis  
Primary Prevention:  In children and adolescents prophylaxis is rarely undertaken and there 
has been few reports that the use of AT concentrate may decrease the incidence of 
thrombosis (78-79)   
In a historically controlled study of adult patients, Mitchell et al (78) reported that the 
incidence of VTE was lower in a cohort of patients who received prophylactic AT 
concentrate but the study did not establish efficacy.  A retrospective comparison of cohort of 
patients at two centers in Canada who had prophylaxis against CNS thrombosis with fresh 
frozen plasma and cryoprecipitate did not develop CVST (80).   
Most paediatric oncology centers do not perform the coagulation screening tests or perform 
AT levels routinely. If prophylaxis is deemed appropriate for a particular patient, it is best 
applied during induction phase of therapy when the majority of VTE events take place. 
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For intracranial thrombohemorrhagic complications, the use of AT concentrates and/or 
cryoprecipitates to replace both AT and fibrinogen, respectively, is a reasonable approach. 
In case of unavailability of AT, fresh frozen plasma (FFP) at a dose of 20 ml/kg can raise 
the AT level by approximately 20%.  However, FFP may also replenish asparagine and, 
thereby, counteract the anti-leukemic effect of ASNase. There is no clear indication from 
the literature about whether further administration of ASNase should be stopped in 
adults after a thrombotic event while on therapy. In children, ASNase is continued under 
cover of low-molecular-weight heparin. Patients with thrombotic events after ASNase 
have been successfully re-challenged with ASNase without recurrence of thrombosis (75). 
In the Dana-Farber Cancer Institute review (63) confirms that, after venous 
thromboembolic events, asparaginase can be restarted after demonstrating clot 
stabilization or improvement by imaging with close monitoring of anticoagulation. 
Therefore, a history of venous thromboernbolic events does not seem to adversely impact 
prognosis.  
The expert panel, Wendy Stock et al (81) in their excellent article published in Leukemia and 
Lymphoma, 2011 detailed the management of ASNase associated VTE and put down the 
recommendation which is being adapted/summarized hereunder:  
1. In adults, activated partial thromboplastin time (APTT), international normalized ratio 
(INR), AT, and fibrinogen levels should be measured prior to ASNase therapy for 
baseline assessment.  
2. Between doses of native ASNase and for 1 week after pegASNase therapy, these tests, 
as well as factor Xa, should be serially monitored as clinically indicated.  
3. AT concentrates and cryoprecipitate infusions should be considered for treatment of 
thrombohemorrhagic events due to AT and fibrinogen deficiency, respectively.  
4. For non-urgent thrombohemorrhagic episodes, fresh frozen plasma should be avoided 
since it contains asparagine and may counteract the anti-leukemic effect of ASNase.  
However, careful follow up is advised for possible evolution of the 
thrombohemorrhagic event into a major one.  
5. For a clinically significant DVT, the patient should be anticoagulated with or without 
AT supplementation, and whether or not it is associated with a central venous line.  
6. Early diagnostic imaging, CT scan and or MRI should be performed in patients with a 
suspected CNS event related to ASNase therapy and urgent consultation of the 
neurologist/ neurosurgeon should be secured and documented. 
7. For CNS thrombosis, the patient should be anticoagulated with or without AT 
supplementation after careful evaluation. 
8. Anti-epileptic medications in patients with thrombohemorrhagic complications should 
be administered prophylactically or therapeutically as appropriate at the discretion of 
the neurologist. 
9. ASNase is discontinued for all clinically significant bleeding or thrombosis and whether 
it is resumed depends on the nature and resolution of the thrombohemorrhagic event 
and outcome of discussion of the case at the tumor board. 
5-Fluorouracil 
This synthetic pyrimidine analogue is an important chemotherapeutic agent for treatment of 
various solid tumors.  The incidence of VTE in patients treated for colorectal cancer with this 
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drug has been reported at 15-17%.  During 5-FU infusion, there is a reduction of protein C 
and an increase level of fibrinopeptide through the action of thrombin (83-84). 
2.5.2 Angiogenic Inhibitors and immunomodulatory agents  
a. Angiogenesis Inhibitors Associated with VTE:  
Angiogenesis is a process involving the proliferation of new blood vessels and plays a 
central role in the growth and metastasis of cancer (85).  The angiogenesis is driven mainly 
by the vascular endothelial growth factor (VEGF).  The signaling pathway of VEGF has been 
a target of many angiogenesis inhibitors including bevacizumab, sorafenib and others (86-
87). Bevacizumab (Avastin, Genentech Inc., South San Francisco California) is a recombinant 
humanized monoclonal neutralizing antibody against VEGF has shown efficacy in 
treatment of many solid tumors including colorectal cancer, non-small cell lung cancer and 
renal cell carcinoma. 
Shobha R Nalluri et al (88) in their metanalysis of 15 randomized controlled trials (RCTs) 
demonstrated that bevacizumab is associated with significantly higher risk of VTE (RR, 
1.33[95% CI 1.13-1.56]; P<0.001) in patients with a variety of metastatic solid tumors and this 
risk is observed for all grades of VTE.  
The thrombogenic effect of bevacizumab may be related to (a) its exposure of the 
subendothelial procoagulant layer and inhibition of the VEGF induced endothelial cell 
regeneration (89), (b) reduction of production of nitric oxide and prostacyclin by 
bevacizumab (90), (c) release of procoagulant molecules from the tumor cells into the 
circulation (91) and (d) increasing the haematocrit and blood viscosity via over production 
of erythropoietin (92). 
b. Thalidomide and its derivative Lenalidomide are immunomodulatory agents with 
antiangiogenic properties through blockade of basic fibroblastic growth factor and 
VEGF and are associated with increased risk of VTE in cancer patients.  This topic has 
been well covered in chapter 5 of this book by Drs Gonzalez-Porras and Mateos. 
2.5.3 Hemopoetic growth factors 
Tumor hypoxia may contribute to the resistance of some tumors to both chemotherapy and 
radiation therapy (93-94).  Many cancer patients are anemic. There are some data from the 
literature indicating that patients who received transfusions to maintain a higher hematocrit 
have improved outcomes with radiation therapy for cervical carcinoma. (95)  
Studies on inducing and maintaining higher haemoglobin (Hb) levels in patients with 
malignant disease by administration of recombinant human erythropoietin (rHuEpo), the 
primary haematopoietic growth factor for erythropoiesis (96), have shown that rHuEpo is 
effective in increasing Hb levels in the majority of anaemic cancer patients (97-98) and that 
this increase is associated with an improvement in patient-reported quality of life. Because 
both fatigue and anemia are common complications of cancer, the use of rHuEpo in patients 
with cancer has increased significantly (99).  Those studies typically have shown that a 
majority of patients will have an erythropoietic response to doses of rHuEpo between 150 
IU/kg and 300 IU/kg given subcutaneously 3 times per week (98, 100). 
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Dusenbery et al (101) in a study of patients receiving rHuEpo along with chemotherapy and 
radiation therapy for cervical carcinoma, reported that 2 of 20 patients had DVT during 
therapy, and 2 other patients had DVT 9 days and 10 days after radiation therapy and 
rHuEpo were discontinued. Although it was a small sample, the rate of 20% in that study is 
similar to the rate found in by Ted Wun et al (102). The combination of chemotherapy and 
radiation may lead to a more vigorous inflammatory response that may predispose patients 
to thrombosis in the background of other predisposing factors.   
In a recent Cochrane meta-analysis of 35 trials representing almost 7000 patients, epoetin or 
darbepoetin treatment was associated with a significantly increased risk for thromboembolic 
events (103).   
Erythropoietin may contribute synergistically to thrombosis in cancer patients through 
several mechanisms. (a) Increasing red cell mass leading to increasing whole blood 
viscosity, (b) Erythropoietin therapy results in reticulocytosis, the metabolically active 
young red blood cells. Elegant studies have demonstrated that metabolically active red 
blood cells augment platelet reactivity in vitro (104-108)  (c) rHuEpo is synergistic with the 
platelet growth factor, thrombopoietin, for platelet activation in vitro (109-110) at 
concentrations that can be achieved pharmacologically in vivo. (d) Erythropoietin has been 
associated with increased platelet reactivity and evidence of endothelial activation when 
administered to healthy male volunteers (111) (e) In vitro data have demonstrated receptor-
mediated endothelial cell activation in response to rHuEpo and that extracellular matrix 
produced by the activated endothelial cells enhanced platelet aggregation and recent 
evidence suggests that platelet-red cell interactions can play a role in venous thrombosis 
(112). 
The role of prophylactic myeloid growth factors: granulocyte colony stimulating factor (G-
CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) in increasing risk of 
cancer-associated thrombosis is unclear (113-114).  
2.5.4 Surgery 
Is a well-known risk factor for development of VTE in patients without cancer. Underlying 
cancer increases the risk of surgery-related VTE by two-fold. Some studies have 
demonstrated that longer time in the operating room, longer time under anesthesia, and 
need for surgical re-exploration is associated with increased risk of VTE in cancer patients 
(37, 115-116).  A study analyzing the effect of surgery in patients with glioma revealed that 
patients who underwent major neurosurgery or brain biopsy were 70% more likely to 
develop VTE within 3 months.  
2.5.5 Indwelling central venous catheters (CVC) 
The use of CVC has improved the management of patients with cancer as they simplified 
the administration of chemotherapy, parental nutrition, antibiotics and other supportive 
intravenous therapy.  However, the CVCs are associated with complications including a 
significant risk of catheter-associated thrombosis (CAT). The risk of VTE associated with 
hospitalization has increased over the last decade a time associated with increased use of 
medical thromboprophylaxis.  The incidence of symptomatic catheter-related DVT in adult 
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cancer patients ranges from 0.3% to 28% while the rate of catheter-related DVT assessed by 
venography is 27–66% (117).  
Some of the factors that may influence the risk of thrombosis of the indwelling central lines 
are (a) site of the catheter: left subclavian lines are at higher risk than the right (b) synthetic 
material: polyvinyl chloride or polyethylene lines are more thrombogenic than are 
polyurethane or siliconized lines (c) number of lumen: triple lumen catheters may be more 
thrombogenic than double lumen  (d) nature of the infusate: infusion of total parenteral 
nutrition fluids through the line have been found to be more thrombogenic than the infusion 
of crystalloid fluids (e) the position of the tip of the catheter located in the superior vena 
cava has almost a three-fold higher risk for thrombosis than that located in the right atrium 
and (f) insertion attempts of ≥2 carries higher risk for catheter related thrombosis. 
Patient with CAT may present with pain, swelling, paresthesia, and prominent veins 
throughout the arm or shoulder.  However, many patients may be asymptomatic. 
Contrast venography is the gold standard for evaluation of patients suspected to have the 
upper extremity thrombosis. However, the non-invasive serial compression ultrasound is 
the standard test for UEDVT evaluation and if this is negative in a patient with high-pretest 
probability of UEDVT then the more expensive and invasive ultrasonography is resolved to. 
In some centers, Color Doppler duplex ultrasound may be the modality of choice for the 
diagnosis of symptomatic CVC-R of UEDVT and for screening of suspected asymptomatic 
thrombosis in specific clinical situations (118)   
Prevention:  Despite the strong association between the CVCs and UEDVT, anticoagulant 
prophylaxis is not recommended. Studies evaluating the use of 1-mg (low dose) warfarin 
gave conflicting results (119-121). 
On the basis of the available data from contemporary trials, it is difficult to recommend 
routine antithrombotic prophylaxis in cancer patients with central venous catheters.  
Institutions are encouraged to assess their rates of catheter-associated thrombosis and 
develop a protocol on how the catheters are inserted and maintained. This will be a useful 
tool to control the rate of complications associated with CVCs. When symptomatic 
thrombosis occurs in association with a catheter, it definitely complicates the clinical care of 
the patient because of the need for anticoagulant therapy and because often the catheter has 
to be removed.   
Management of Catheter Associated Thrombosis 
Treatment: ACCP guidelines recommend treating UEDVT patient with UH or LMWH and 
warfarin (INR 2-3) for at least 3-months (122).   
• Right Atrial Thrombus 
a. Surgical management 
These thrombi may impede atrial or ventricular inflow and cause sudden death. For a 
symptomatic patient with a large mobile thrombus, surgical thrombectomy is strongly 
recommended (123-124) and the catheter should also be explanted (125, 126, 127). Early 
involvement of the cardiologist, the cardiac surgeon and intensivist is advisable for 
coordinated optimum management. 
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b. Medical management 
A completely dissolved right atrial thrombus case without side effects was reported by 
Adamovich et al in a neonate after 5 days’ with infusion of urokinase and heparin (128). 
Cesaro et al reported on a successful pediatric case that was treated with recombinant tissue 
plasminogen activator (rt-PA) and heparin for 6 days without significant side effects (129). 
Korones et al favoured conservative management for small-sized thrombus with no 
intervention but close follow up for evidence of growth in size is warranted. However, for a 
moderate-sized thrombus there is a need for anticoagulation rather than surgical 
thrombectomy (123). If medical treatment fails then surgical thrombectomy should be 
resolved to. In adults, medical treatment has been tried in only a few reported cases because 
it is believed that, even though antithrombotic agents may stabilize or regress catheter-
related RA thrombi, anticoagulated patients remain at risk of pulmonary embolism and 
need to have surgical thrombectomy eventually (130-132).  
• Central Venous Thrombosis 
a. Surgical management  
The course of action for implantable venous access device (IVAD) after CVT is variable. 
Medical antithrombotic treatment was widely applied, but most of the devices were still 
explanted and some were removed before medical treatment is started (5,6) and some were 
explanted after fibrinolytic, antithrombotic or anticoagulant treatment failed (133-135). The 
reasons for explantation of IVAD are (a) prevention of thrombosis progression, especially in 
the case of SVC syndrome, (b) persistent pain, (c) combined with a documented infection 
and extravasation. However, Lokich et al (136) reported that the vascular occlusion rarely 
resolve after the explantation. 
b. Medical management 
For all CVT patients with or without IVAD explantation, antithrombotic treatment is 
necessary. Removal of the device should be decided by clinical necessity for venous access 
or by evidence of pulmonary embolism (134), especially in patients with very difficult 
venous access.  
c. Unfractionated Heparin 
Intravenous UFH is the initial treatment of choice for acute CVT. UFH can prevent clot 
propagation but does not dissolve it and, therefore, recanalization may not develop. UFH 
can be given by continuous intravenous infusion for 5–10 days, starting with a bolus of 5000 
IU followed by 30,000–35,000 IU/day, with activated partial thromboplastin time of 1.5–2.5 
times the control (137). 
d. Low Molecular Weight Heparin 
In view of the many advantages particularly the subcutaneous route q12 hours dosage, no 
need for laboratory and home treatment basis of the LMWH over the UFH, many experts 
favor its use for management of acute CVT 
e. Fibrinolytic agents 
Fibrinolytic agents, such as recombinant tissue plasminogen activator (rt-PA), streptokinase, 
and urokinase are usually effective for the lysis of fresh thrombi. Resolution of thrombi is 
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more significant in acute occlusions than in CVT, which is always detected after a period of 
time i.e. chronic organized thrombosis. Although some studies mentioned their usage, 
antithrombotic agents are still the first choice (134,138). 
• Intraluminal thrombotic occlusion 
a. Surgical management 
Surgical explantation of the device should be considered after fibrinolytics have failed or 
therapy has been terminated because of its minor severity and the high success rate of 
medical treatment (134,139-140).  
b. Medical treatment 
Fibrinolytic agents, such as rt-PA, urokinase and streptokinase, have been used in recent 
decades to lyse intraluminal thrombi, to restore device patency and to avoid catheter 
removal. Intraluminal installation of fibrinolytic agents is still considered the safest and 
most effective therapy for the treatment of IVAD intraluminal thrombotic occlusions. These 
agents are associated with some complications e.g. bleeding, hypersensitivity reactions, 
arrhythmias, hypotension, fever, nausea or vomiting and the attending physician is advised 
to make note of this at the time when a decision is made. 
c. Recombinant tissue-plasminogen activator (rt-PA) 
Alteplase is the most popular and effective rt-PA used in the treatment of thrombotic 
occlusions. It is a serine protease that activates plasminogen to plasmin in the cleavage of 
thrombus-bound fibrin. In adult patients, 2 mg alteplase in 2 mL sterile water may be 
injected into the occluded catheter. Restoration of function is assessed 30–120 minutes later 
and if function is not restored, a second attempt with the same dose is performed (141-142). 
In 64-86% of patients successful treatment was achieved after a single dose, and two doses 
achieved 81–94% success.  In addition, alteplase has the advantages of a low incidence of 
allergic reactions (< 0.02%) and no documented reports of sustained antibody formation 
after administration (134). Although small dose alteplase is so far not commercially 
available, large dose alteplase can be split into unit doses and cryopreserved at –20°C for 30 
days (141). Reconstruction to small dose aliquots makes this a cost-effective treatment 
without compromising safety and efficacy (141-142). However, the production of a single-
dose rt-PA vial is still needed, not only for small institutions but also as a convenient, 
economically sound and safe agent for oncologic patients. 
d. Urokinase 
In 1999, the FDA reported on microorganism contamination of urokinase and issued a 
warning about variations in quality control during manufacture, recommending that 
urokinase be restricted to specific patients in whom the physician has judged urokinase to 
be critical to the clinical situation (143). 
e. Streptokinase 
Although streptokinase can resolve occlusions without hemorrhagic side effects or 
coagulation changes.  Its use is fraud with some difficulties: allergic reactions and the 
induction of antibody formation, fever and shivering in 1–4% and anaphylactic reactions 
0.1% of patients these risks/issues led to the restriction of its usage (141,144). The producers 
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of streptokinase, AstraZeneca, released an Important Safety Information letter on 
streptokinase in December 1999 and warned that there is a risk of significant allergic 
reactions and that streptokinase is not indicated for restoration of IVAD patency (144). 
2.5.6 Radiation 
There are limited data on the effect of isolated radiation modality on risk of cancer-associated 
thrombosis. However, the combination of chemotherapy and radiation could lead to a more 
vigorous inflammatory response that may predispose patients to thrombosis in the setting of 
other predisposing factors. In a study of patients receiving rHuEpo along with chemotherapy 
and radiation therapy for cervical carcinoma, Dusenbery et al (101) reported that 2 of 20 
patients had DVT during therapy, and 2 other patients had DVT 9 days and 10 days after 
radiation therapy and rHuEpo were discontinued. Although it was a small sample, the rate of 
20% in that study is remarkably close to the rate found by other investigators.  Large, 
randomized studies of combined chemotherapy and radiation therapy in patients with 
carcinoma of the cervix did not report on the rate of venous thrombosis (145-148). 
2.5.7 Hormonal therapy: Tamoxifen and exemestane 
Tamoxifen was discovered by pharmaceutical company Imperial Chemical Industries (now 
AstraZeneca) and is sold under the trade names Nolvadex, Istubal, and Valodex. However, 
the drug, even before its patent expiration, was and still widely referred to by its generic 
name “tamoxifen.”       
Tamoxifen binds to estrogen receptors but produces both estrogenic and antiestrogenic 
effects. It reduces circulating insulin-like growth factor-1, inhibits angiogenesis, and induces 
apoptosis (149) 
Tamoxifen is highly beneficial as adjuvant therapy for breast cancer, and more recently, its 
effectiveness has been demonstrated for prevention of breast cancer in high-risk women. 
(150-151) 
The most frequent side effect in patients treated with tamoxifen versus placebo was a 
doubling of the rate of DVT and PE: 118 versus 62 cases and a similar increase in superficial 
phlebitis (68 versus 30 cases) (152) A systematic review of adjuvant hormonal therapy for 
breast cancer estimated that women treated with 5 years of tamoxifen have a 1.5-7.1 fold 
increased risk of VTE compared to women treated with placebo or on observation only. 
(153)   
As to the evaluation of women who are about to initiate tamoxifen to prevent the 
development of breast cancer, the question raised is cost: benefit ratio of tamoxifen therapy 
if the patient have risk factors for DVT or PE.  On the basis of the solid data favoring 
tamoxifen, the prevention of breast cancer should take priority over the risk of venous 
thromboembolism.  If the risk of developing DVT is high, it is reasonable to go for 
concomitant anticoagulation with Coumadin (INR 2-3) for the planned treatment period 
with tamoxifen.  
However VTE risk may become less problematic in breast cancer patients as the third-
generation oral aromatase inhibitors, such as the irreversible steroidal inactivator 
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exemestane, are being used in place of tamoxifen for long-term prophylaxis after initial 
therapy of breast cancer.  Exemestane is the generic name for the brand-name drug 
Aromasin and works by binding irreversibly to the body’s aromastase enzyme, which is 
responsible for producing estrogen.  Many breast cancer cells depend on estrogen to grow 
and multiply quickly.  Once the aromatase inhibitor binds to the aromastase enzyme, the 
bound aromatase enzyme can no longer produce estrogen.  This drug caused lack of 
estrogen “starves” estrogen- dependent breast cancer cells, preventing them from 
multiplying. Coombes et al, in a trial in which 4742 breast cancer patients were 
randomized to continue tamoxifen or to switch to exemestane.  Those receiving 
exemestane experienced improvement in disease-free survival (154-155) The adjusted 
hazard ratio was 0.67 (95% CI 0.56 to 0.82, P<0.001) and the rate of thromboembolic events 
was almost halved in those receiving exemestane as compared with tamoxifen (1.3% 
versus 2.4%, p=0.007). 
3. VTE and occult cancer 
Thrombosis can be the first manifestation of malignancy. Patients who present with 
idiopathic or unprovoked DVT are more likely to be diagnosed with cancer during follow-
up than patients with secondary DVT. In pooled analyses of cohort studies, the odds ratio 
for subsequent cancer in patients presenting with idiopathic VTE compared with patients 
with secondary VTE is 4.8 (156).  About 10% of patients with idiopathic VTE were diagnosed 
with subsequent cancers over the next 5–10 years. More than 75% of these cases were 
reported within the first year after the diagnosis of DVT (157).  
Prins et al studied (158) the incidence of newly diagnosed malignancy in patients with 
unexplained venous thromboembolism during the first year after a thromboembolic event in 
comparison to controls (odds ratio, 3.9-36). The authors used extensive screening with 
computed tomography, endoscopy and tumor markers and stated that they identify most of 
these undetected malignancies. However, the authors continued, approximately half of 
these can also be identified based on a simple clinical evaluation.  
Monreal et al (159) reported on retrospective analysis of our 5-year experience with a series 
of 674 consecutive otherwise healthy patients, and a more restricted battery of diagnostic 
tests including: abdominal CT-scan; carcinoembryonic levels, and prostate-specific antigen 
levels.  The authors reported that cancer was more commonly found in patients with 
idiopathic VTE: 13/105 patients (12%) versus 10/569 patients (2%); p <0.01; O.R.: 7.9 (95% 
CI: 3.14-20.09). During the same period of time they diagnosed VTE in 147 patients with 
previously known cancer. When overall considered, VTE was the first sign of malignancy in 
most patients with prostatic and pancreatic carcinoma. However, most patients with breast, 
lung, uterine and brain cancers developed VTE as a terminal event of the disease (159). 
Piccioli et al (160) also concurred with Monreal et al (159) that the diagnosis of venous 
thrombosis although may help to uncover previously occult carcinoma by prompting a 
complete physical examination, chest roentgenography, and mammography, extensive 
cancer screening with computed tomography to neck, chest, abdomen and pelvis or 
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In another publication, Piccioli et al (161) reported that patients with symptomatic 
idiopathic venous thromboembolism and apparently cancer-free have an approximate 10% 
incidence of subsequent cancer. In their study, apparently cancer-free patients with acute 
idiopathic venous thromboembolism were randomized to either the strategy of extensive 
screening for occult cancer or to no further testing. Patients had a 2-year follow-up period. 
Of the 201 patients, 99 were allocated to the extensive screening group and 102 to the control 
group. In 13 (13.1%) patients, the extensive screening identified occult cancer. In the 
extensive screening group, a single (1.0%) malignancy became apparent during follow-up, 
whereas in the control group a total of 10 (9.8%) malignancies became symptomatic [relative 
risk, 9.7 (95% CI, 1.3–36.8; P < 0.01]. Overall, malignancies identified in the extensive 
screening group were at an earlier stage and the mean delay to diagnosis was reduced from 
11.6 to 1.0 months (P < 0.001). Cancer-related mortality during the 2 years follow-up period 
occurred in two (2.0%) of the 99 patients of the extensive screening group vs. four (3.9%) of 
the 102 control patients [absolute difference, 1.9% (95% CI,) 5.5–10.9)]. 
Rickles et al (162) stated that while migratory thrombophlebitis is a clear indicator of an 
underlying neoplasm, the risk of cancer in patients with the more typical form of VTE has 
been the subject of intense debate over recent years. The authors concluded that, the cost-
effectiveness of aggressive screening for cancer in patients with VTE remains questionable. 
Nordström, M et al (163) conducted a prospective study of 366 patients in Malmo, Sweden, 
who had treatment after positive results on venography reported an overall incidence of 
deep venous thrombosis of 159 per 100 000 inhabitants per year.  At the time of diagnosis of 
deep venous thrombosis, 71 patients (19%) had a known cancer and a further 19 (5%) 
developed cancer within the following year. Eight of the cancers were obvious at the time of 
diagnosis of the deep venous thrombosis and 11 were occult.  
To date, there is very little evidence that routine cancer screening is indicated or cost-
effective in patients with unprovoked thrombosis. Nonetheless, it is prudent to perform a 
comprehensive history and physical exam and check basic blood work with relevant tumor 
markers, as deemed appropriate, in patients with unprovoked thrombosis because about 
90% of occult cancers can be detected using this conservative approach (164-165). 
At our institutions, when performing pulmonary artery CTA and CTV for unprovoked VTE, 
our radiologist analyzes all information produced by the imaging examination. An attentive 
analysis of the entire thoracic and abdominal structures on all pulmonary artery CTA and 
CTV examinations is routine. Careful evaluation is also made in hospitalized patients in 
whom thromboembolic disease is discovered incidentally. In such patients, pulmonary 
artery CTA and CTV is considered a cancer screening procedure with an increased 
likelihood of finding an occult malignancy. When the CTV examination begins at the level of 
the diaphragm instead of below the level of the iliac crest, it permits the detection of venous 
thrombosis and serves as a simultaneous screening for possible underlying malignant 
disease.  
4. The use of biomarkers for risk assessment for VTE in cancer patients 
Despite the well documented association of cancer with increased risk of thrombosis, 
clinical studies have not consistently demonstrated improved outcomes with 
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thromboprophylaxis in all groups of cancer patients, and hence their risk for VTE in view of 
the heterogenity of cancer (166).  
Moreover, treatment of VTE in patients with cancer or use of pharmacological agents for 
thromboprophylaxis is more difficult and is associated with considerable therapeutic 
challenges in view of thrombocytopenia caused by some chemotherapeutic agents and 
morbidity associated with VTE in often medically compromised cancer patients (32, 167) 
Therefore, identification of a high-risk subgroup of cancer patients who will benefit from 
primary thromboprophylaxis is well justified. Recent data have identified multiple clinical 
risk factors as depicted under patient-, disease- and treatment-related risk factors above as 
well as biomarkers predictive of VTE in cancer patients. Biomarkers associated with 
increased risk of cancer associated VTE include leukocyte count, platelet count, and levels of 
tissue factor, P-selectin, D-dimer and CRP as discussed below.  
a. Leukocyte count: Leukocytosis was identified as independent risk factor associated 
with increased risk of VTE in cancer patients before initiating chemotherapy (OR 2.0). 
VTE occurred in 4.5% patients with baseline leukocytosis, WBC ≥11x109/L, compared 
to (1.8%) without leukocytosis (p < 0.0001). In a prospective observational study of 3303 
ambulatory cancer patients: “Awareness of Neutropenia in Chemotherapy” Study 
Group Registry, leukocyte count >11.0x109/L was also reported to be independently 
associated with an increased risk of subsequent VTE. Leukocytosis may be a marker of 
the aggressiveness of the cancer cells or represent a direct causative role in mediating 
cancer-associated thrombosis, through, as yet, unknown mechanisms (168-169). 
b. Platelet count: Thrombocytosis is often observed in cancer patients and elevated 
platelet counts correlates with an activation of coagulation.  In several studies of cancer 
patients, an elevated platelet count (≥350x109/l) prior to starting chemotherapy was 
found to be strongly associated with VTE (21, 19). The incidence of VTE was 4-7.9% in 
patients with a pre-chemotherapy platelet count ≥350x109/l compared to 1.25% in 
patients with lower platelet counts. The increased risk of VTE with higher platelet 
counts persisted while the patients were on chemotherapy and these patients had a 3-
fold higher rate of VTE (32). 
c. D-Dimer is a degradation product of cross-linked fibrin that is formed after thrombin-
generated fibrin clots have been degraded by plasmin. Elevated fibrin D-dimer level 
(HR, 1.8) and elevated prothrombin split products (HR, 2.0) have recently been shown 
to be associated with increased risk of VTE in a large prospective study of cancer 
patients (170). D-dimer was also elevated in metastatic breast cancer patients compared 
to normal controls (171). These and other data suggest that D-dimer levels may be a 
predictor of VTE in cancer patients.  
d. Clotting factor VIII (VIII:C) This factor plays an important role in the coagulation 
cascade. In non-cancer patients, a high FVIII: C activity has been established as a risk 
factor for primary and recurrent VTE (25-26, 51).  In a prospective cohort study, a 
significant association was found between FVIII:C levels and the risk of symptomatic 
VTE in cancer patients (51). In an analysis of cancer patients including solid cancers and 
haematological malignancies, the cumulative probability of VTE after 6 months was 
14% in patients with elevated FVIII (cut-off: 232%) as opposed to 4% in those with 
normal levels (p = 0.001). These results demonstrate that elevated FVIII:C levels in 
cancer patients proved to be a valuable, independent risk marker for VTE, predicting an 
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almost 3-fold increased VTE risk (172). Cumulative probability of VTE after 6 months 
was 14% in patients with elevated FVIII:C levels  
e. The prothrombin fragment 1+2 (F1+2) is released when activated factor X cleaves 
prothrombin to thrombin and reflects the in-vivo thrombin generation.  A systematic 
activation of coagulation has been observed in cancer patients which is reflected by 
elevated plasma levels of global coagulation markers, such as D-Dimer or prothrombin 
fragment 1+2 (F1+2) (49, 173). 
f. Tissue factor (TF) is a transmembrane glycoprotein present on subendothelial tissue, 
platelets, and leukocytes that initiates coagulation and plays a critical role in regulating 
hemostasis and thrombosis (174-175). TF expression has been shown to be associated 
with increased angiogenesis in various solid neoplasms, including hepatocellular, 
colorectal and prostate cancers as well as in haematologic malignancies and play a role 
in cancer-associated thrombosis (176-177).  TF induction was shown to be an early event 
in the development of pancreatic cancer and that the level of TF expression correlates 
with increased angiogenesis and with subsequent development of symptomatic VTE 
(176-179). 
VTE was 4-fold more common (p = 0.04) among patients with high TF-expressing 
carcinomas (20%) than among those with low TF-expressing carcinomas (5.5%). There is a 
potential for circulating TF to be used as predictive biomarker for pancreatic cancer 
associated VTE. VTE was 4-fold more common (p = 0.04) among patients with high TF-
expressing carcinomas (26.5%) than among those with low TF-expressing carcinomas (5.5%). 
In another study, TF expression correlated with subsequent VTE in a series of patients with 
ovarian cancer (173).  
Furthermore, a retrospective analysis of cancer patients without VTE, revealed a 1-year 
cumulative incidence of VTE of 34.8% in patients with TF-bearing MPs versus 0% in those 
without detectable TF-bearing MPs (p= 0.002). 
g. Soluble P-selectin (sPS): This is a cell adhesion molecule found in the membranes of 
platelets and endothelial cells (Weibel–Palade bodies) where it can function as a 
receptor and mediate cell adhesion via binding to several ligands. The interaction of 
sPS with PSGL-1 expressed on the majority of leukocytes results in the release of 
procoagulant, tissue factor-rich microparticles (MPs) from leukocytes, endothelial 
cells, platelets and cancer cells (179).  In case-control studies of non-cancer patients 
with a history of VTE and healthy subjects without a history of venous or arterial 
thrombosis, high plasma levels of sPS have been demonstrated to be strongly 
associated with VTE (27, 35). In a multivariate analysis of the prospective 
observational Vienna Cancer and Thrombosis Study, elevated sPS (cutoff level, 53.1 
mg/mL) was a statistically significant risk factor for VTE after adjustment for age, 
sex, surgery, chemotherapy and radiotherapy (HR = 2.6) and the cumulative 
probability of VTE after 6 months was 11.9% in patients with high sPS and 3.7% in 
those normal levels (p = .002) (180). 
C- Reactive Protein 
C-reactive protein (CRP) is an inflammatory marker produced by the liver and adipocytes. 
In a prospective study, CRP was significantly associated with increased risk of VTE by 
multivariate analysis (181-183) 
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Patient Related Factors • Age - > 60 years 
• Gender 
• Race 
• Previous thrombotic episode   
• Obesity:  BMI ≥ 35 kg/m2 
• Chronic co-morbid Medical Conditions 
Disease Related Factors • Tumors type 
• Initial cancer stage 
• Biological aggressiveness of cancer   
• Rate of metastatic spread 
Treatment Related Factors • Chemotherapy 
• Anti-angiogenic and immunomodulatory 
agents  
• Use of Hemopoetic growth factors 
• Surgery  
• Indwelling central venous catheters 
• Radiation 













Biomarkers • Leukocyte count    ≥ 11x109 /L 
• Platelet count        ≥ 350 x109 /L 
• D-Dimer 
• Clotting factor VIII 
• The prothrombin fragment 
• Tissue factor (TF) 
• Soluble P-selectin 
• C-Reactive protein 
Table 1. Summary of the Risk Factors for VTE in Cancer Patients 
5. VTE in haematological malignancies 
Although the association between malignancy and thrombosis has been well recognized, 
less is known about the risk of thrombosis in patients with acute leukemia and the impact of 
VTE on survival. Certainly there is abundant biochemical evidence for thrombin generation 
and disseminated intravascular coagulation in patients with leukemia (184). The few single-
center reports of the incidence of venous thrombosis in patients with leukaemia have 
focused primarily on children with acute lymphoblastic leukaemia. These studies have 
suggested the cumulative incidence varies between 2% and 10.6% (185-186). 
Patients with haematologic malignancies are at high risk of thrombotic or haemorrhagic 
complications. The incidence of VTE events varies considerably and is influenced by many 
factors, including the type of disease, chemotherapy used, and whether a central venous 
device is inserted.  As in solid tumors, a number of clinical risk factors have been identified 
and contribute to the increasing thrombotic rate in haematologic malignancies. Biologic 
www.intechopen.com
 
Venous Thromboembolism in Cancer Patients 
 
91 
properties of the tumor cells can influence the hypercoagulable state of patients with these 
malignancies by several mechanisms. Of interest, oncogenes responsible for haematological 
neoplastic transformation in leukemia also may be involved in haemostatic activation.  
• VTE in Central Nervous System Lymphoma  
Patients with brain tumors are at particularly high risk for VTE, and many studies found 
that the hazard for deep vein thrombosis in patients with malignant glioma may reach 28% 
(187-188) This high risk is maintained throughout the course of an active disease and during 
treatment, and not just in the immediate postoperative period (188). Risk factors for VTE in 
patients with glioma include the presence of paraparesis, a histologic diagnosis of 
glioblastoma multiforme, age ≥ 60 years, large tumor size, the use of chemotherapy, and 
length of surgery of > 4 hours. Because of the high incidence of VTE, patients who are 
treated for brain tumors are usually considered for long term prophylactic anticoagulation 
as deemed appropriate for a particular patient (189-190). 
• VTE in Non-Hodgkin Lymphoma  
The incidence of clinical VTE in patients with malignant lymphoma reportedly ranges 
between 6.6% and 13.3% (187, 190-194) In one study, 50% of patients had a bulky tumor 
compressing a vein, 25% of patients had a central catheter at the thrombosed vein, and, in 
the other patients, thrombosis was attributed to paraneoplasia or to chemotherapy (187) 
Conlon SJ et al (194) reported the results of retrospective analysis of patients with a total of 
18 653 cases on the NCI Working Formulation: there were 5496 low grade NHL, 12 251 
aggressive NHL and 906 high-grade lymphoma cases. The cumulative incidence (CI) of VTE 
24 months from diagnosis was 4.0%. The CI of VTE at 24 months were significantly different 
for the distinct lymphoma groups (p< 0.001, Chi-square and comparisons showed this 
difference to be significant only between the low grade and other histologies. Of 742 cases 
that had VTE, 454 died within 2 years (61%). For those without VTE, 7274 of 17911 (41%) 
died within 2 years. This difference was statistically significant (p <  0.001, Chi-square).  
• VTE In Patient with Acute Leukemia  
A population- based cohort study (1993-1999) to determine the incidence and risk factors 
associated with development of VTE among Californians diagnosed with acute leukemia 
(1993-1999) was reported in Blood 2009, by Ku GH et al (195).  Among 5394 cases of AML, 
the 2-year cumulative incidence of VTE was 281 (5.2%) and 64% of VTE events occurred 
within 3 months of AML diagnosis.  The authors reported that, in AML patients, female sex, 
older age, number of co-morbid conditions, presence of CVC were significant predictors for 
development of VTE within one year following diagnosis of acute leukemia but the event of 
VTE was not associated with poor survival in AML patients in the studied group.  Among 
2482 case of ALL, the 2-year incidence of VTE was 4.5% and risk factors in this group were 
presence of CVC, older age and number of chronic co-morbidities. In this study, 
development of VTE in ALL patients was associated with a 40% increase of dying within 
one year. 
In the abstract #6595 published in JCO 2011 by Luong NV et al from MD Anderson Cancer 
Center, USA (196) of a retrospective chart review to determine the prevalence of VTE prior 
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to treatment and recurrence of VTE.  Records of 299 ALL patients and 996 AML patients 
were included (Nov 1991-May 2005).  The authors concluded that acute leukemia patients 
have a high prevalence of VTE but the occurrence of VTE prior to initiation of chemotherapy 
was not associated with poor prognosis similar finding to that reported by Ku GH et al. 
Blast cells with their procoagulant properties, central venous catheters, chemotherapeutic 
agents (as discussed earlier in this chapter) concomitant infections, patient-and supportive 
treatment related factors are major determinants of haemostatic mechanism activation in 
acute leukemia. The clinical manifestations range from VTE to diffuse life-threatening 
hemorrhage. Anti-coagulant therapy in this clinical setting is fraud with major difficulties 
as the patients are at very high risk of haemorrhage because of thrombocytopenia.  To 
date, no guidelines are available for prophylaxis or treatment of VTE in this group of 
patients (197)      
• VTE in Acute Promyelocytic Leukemia 
The use of the differentiating agent all-trans-retinoic acid (ATRA) in the treatment of APL 
allowed achievement of complete remission in more than 90% of the cases and improved 
dramatically the coagulopathy typical of this disease (198). The modifications induced by 
ATRA in the balance between procoagulant and fibrinolytic properties of the pathological 
promyelocytes before complete differentiation have been proposed to induce a 
prothrombotic effect (199).  
• VTE in Multiple Myeloma  
Multiple myeloma (MM) has been associated with increased risk of VTE events.  Specific 
risk factors for VTE in MM are production of autoantibodies to haemostatic factors, high 
incidence of acquired protein C resistance, increased VIII:C levels and VWF and increase of 
production of inflammatory cytokines e.g. IL-6, TNF and C-reactive protein and 
paraprotein. These unique risk factors may operate along other common cancer VTE risk 
factors e.g. age, immobility, cancer procoagulant factors and chemotherapy.  
Treatment regimens for MM include thalidomide, Lenalidomide combined with 
glucocorticoids and cytotoxic chemotherapy are associated with an increased risk of VTE 
particularly when the immunomodulatory agents are combined with anthracyclines. 
Combination chemotherapy including thalidomide plus dexamethasone and/or alkylating 
agents are associated with intermediate risk for VTE.  The use of newer immunomodulator 
e.g. bortezomib seem to reduce the VTE risk (200). This topic has been well covered in 
chapter 5 of the book.   
• VTE in Monoclonal gammopathy of undetermined significance      
In 2004, Sallah S et al and Srkalovic G et al published in Ann Oncol and cancer respectively 
(201-202) two small hospital based studies on the association of monoclonal gammopathy of 
undetermined significance (MGUS) and subsequent risk of DVT and reported an elevated risk 
of DVT in MGUS. Kristinsson Y et al (203) conducted a retrospective study on 4,196,197 
veterans hospitalized at least once.  MM was identified in 2374 (0.06%) cases of MGUS 6192 
(0.15%). A total of 31 and 151 DVTs occurred among MGUS and multiple myeloma, 
respectively (crude incidence 31 and 8.7 per 1000 person-years, respectively).  The RR of DVT 
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after a diagnosis of MGUS and MM was 3.3 and 9.2 respectively with excess risk of DVT in the 
first year of diagnosis.  Compared to the background population, patients with multiple 
myeloma have a 9-fold increased risk of developing DVT especially during the first year of 
diagnosis while the risk for DVT in MGUS was stable at 3-fold increased risk over time with 
no statistical association between DVT in MGUS and risk for progression into MM. 
• VTE in Myelodysplastic Syndrome 
Yang X et al (204), in 2009, reported a total of 7764 MDS patient who were prescribed 
Lenalidomide during the first two years of its commercial use in the USA.  VTE was 
reported in 41 patients (rate of 0.53%) denoting a computed signal that did not exceed the 
statistical threshold for identification of a significant disproportional signal for VTE in MDS 
on Lenalidomide without erythropoietin. However, the authors found that a 
disproportional signal of VTE where erythropoietin was concurrently administered with 
Lenalidomide.  
• VTE in Myeloproliferative Neoplasms 
Life expectancy of patients with myeloproliferative neoplasms (MPNs) and particularly that 
of subjects with polycythemia vera (PV) and essential thrombocythemia (ET) has 
significantly increased over the last three decades, largely due to the use of cytoreductive 
treatments. Currently, PRV and ET are considered relatively benign diseases in which the 
main objective of treatment strategy is the prevention of thrombotic events. Widespread use 
of routine haematologic screening and novel diagnostic tools greatly facilitate disease 
recognition and treatment. This helps to prevent a significant number of early vascular 
events that still constitute the first disease manifestation in approximately one-third of 
patients (205).  We can also expect that new therapeutic options and appropriate use of 
aspirin will result in a further reduction of morbidity and mortality. One of the unmet needs 
of PRV and ET is validated methods for vascular risk stratification. The evaluation of the 
thrombotic risk in the individual patients, as reported by Barbui et al. in their paper (206). 
The pathogenesis of thrombosis in myeloproliferative neoplasms has been extensively 
investigated by focusing in particular on the possible contribution of disease related 
haemostatic abnormalities. However, the pathogenesis of thrombosis appears to be 
multifactorial.  Red blood cell, platelet, and leukocyte abnormalities, both qualitative and 
quantitative, are likely to play a key-role in myeloproliferative neoplasm thrombophilia. 
High shear stress of the vessel wall, due to blood hyperviscosity, accounts for chronic 
endothelial dysfunction and platelet and leukocyte activation. 
Platelets and endothelial cells play a pivotal role in regulating blood flow, both cells might 
contribute to determine a prothrombotic microenvironment in myeloproliferative neoplasm 
patients by producing more soluble selectins and less nitric oxide, likely as a consequence of 
inflammation (207).  
According to the data of Barbui et al. (208) it is intriguing to consider the possibility that 
pentraxin 3 response to inflammation in subjects with high JAK2 burden might contribute to 
lower or enhance the thrombotic risk. More generally the association between JAK2 
mutation, inflammation and thrombotic risk deserves scientific attention also for other 
speculative and practical purposes.  
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6. The scoring system for risk assessment for VTE in cancer patients 
The development of predictive risk assessment model in non-cancer patients has helped to 
stratify patients according to their VTE risk and tailor thromboprophylaxis accordingly. 
Some models in surgical patients stratified patients according to the type of operation 
(major or minor), age and the presence of additional risk factors eg. cancer, prior VTE, 
obesity, co-morbid medical conditions.  
In cancer patients, risk stratification is a dynamic process depending on the type and stage 
of cancer, performance status, and supportive and specific cancer therapy.  A model-based 
approach that incorporates multiple risk factors for VTE can help identify the high-risk 
subgroups in the cancer population and would allow for a directed prophylactic strategy to 
improve outcomes of management and sparing the low risk patients from unnecessary 
anticoagulation therapy with its complications, social and financial burden. The ideal score 
model has to be simple, sensitive, specific and well validated. 
Khorana AA et al (209) developed a simple model for predicting chemotherapy-associated 
VTE using baseline clinical and laboratory variables. The association of VTE with multiple 
variables was characterized in a derivation cohort of 2701 cancer outpatients from a 
prospective observational study. A risk model was derived and validated in an independent 
cohort of 1365 patients from the same study.  Five (2 clinical and 3 laboratory) predictive 
variables were identified in a multivariate model: site of cancer (2 points for very high-risk 
site, 1 point for high-risk site), platelet count of ≥350 × 109/L, Hb <100 g/L (10 g/dL) and/or 
use of erythropoiesis-stimulating agents, WBC ≥11 × 109/L, and BMI of ≥35 kg/m2 or more 
(1 point each). Rates of VTE in the derivation and validation cohorts, respectively, were 0.8% 
and 0.3% in low-risk (score = 0), 1.8% and 2% in intermediate-risk (score = 1-2), and 7.1% 
and 6.7% in high-risk (score ≥ 3) category over a median of 2.5 months (C-statistic = 0.7 for 
both cohorts). Khorana AA et al stated that their model can identify patients with a nearly 





Site of Cancer  
     Very high risk (stomach, pancreas) 2 
     High risk (lung, lymphoma, gynecologic, bladder, testicular) 1 
Prechemotherapy platelet count  ≥ 350x10/L  1 
Hemoglobin level ≤ 10g/dl or use or erythropoietin  1 
Prechemotherapy leukocyte count more than 11000/mm3 1 
Body mass index 35 kg/m2 or more 1 
Table 2. Predictive model for chemotherapy-associated VTE  
Adapted from Khorana et al. (209) with permission 
To improve prediction of VTE in cancer patients, Ay C et al (210) performed a prospective 
and observational cohort study of patients with newly diagnosed cancer or progression of 
disease after remission. Khorana’s risk scoring model for prediction of VTE that included 
clinical (tumor entity and body mass index) and laboratory (Hb, platelet and WBC count) 
parameters was expanded by incorporating 2 biomarkers, soluble P-selectin, and D-Dimer. 
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Of 819 patients 61 (7.4%) experienced VTE during a median follow-up of 656 days. The 
cumulative VTE probability in the original risk model after 6 months was 17.7% in patients 
with the highest risk score (≥ 3, n = 93), 9.6% in those with score 2 (n = 221), 3.8% in those 
with score 1 (n = 229) and 1.5% in those with score 0 (n = 276). In the expanded risk model, 
the cumulative VTE probability after 6 months in patients with the highest score (≥ 5, n = 30) 
was 35.0% and 10.3% in those with an intermediate score (score 3, n = 130) as opposed to 
only 1.0% in patients with score 0 (n = 200); the hazard ratio of patients with the highest 
compared with those with the lowest score was 25.9 (8.0-84.6).  The authors demonstrated 
that clinical and standard laboratory parameters with addition of biomarkers enable 
prediction of VTE and allow identification of cancer patients at high or low risk of VTE. 
Ay C et al concluded that with expanded risk model, which included sP-selectin ≥53.1 
mg/ml and D-Dimer ≥1.44 mg/ml, (2 biomarkers) the risk prediction can be considerably 
improved. In patients with the highest compared with patients with the lowest risk, the 
probability for VTE was 26-fold higher. 
The advantage of the “Khorana-Score” is that all parameters of this risk model are routinely 
determined in cancer patients at diagnosis. 
7. Prevention of venous thromboembolism in cancer patients 
Using Khorana risk scoring model or Ay Cihan et al expanded scoring model, it is within 
the reach of the attending hematologist/oncologist to stratify his/her cancer patient into one 
of the VTE risk groups:  very high, high, intermediate or low and consider the patient for 
thromboprophylaxis in a patient-focused approach.   
It also well understood that prophylaxis with antithrombotic agents can be problematic in 
cancer patients because they are at increased risk for anticoagulant induced bleeding. 
However, prophylaxis has been shown to be beneficial in certain high-risk populations such 
as post-surgical or hospitalized cancer patients but data in the ambulatory settings are 
conflicting.  
7.1 Prophylaxis in surgical cancer patients      
In general, surgery for cancer increases the risk of VTE and adequate prophylaxis has been 
shown to reduce VTE rates significantly [99,100]. A number of studies have shown that 
patients with cancer who undergo a specific type of major surgery have a 2-4 fold higher 
incidence of postoperative VTE compared with patients without cancer.  The risk of 
venographically proven DVT varies from 20% to 40% and the risk of fatal PE is 
approximately 1%.  Therefore, routine prophylaxis with anticoagulant therapy is strongly 
recommended, both in the immediate post-operative setting and in the extended period 
following major surgery.  
The agents used most widely for prophylaxis in surgical patients are unfractionated heparin 
(UFH) and low-molecular- weight heparin (LMWH). Meta-analysis of randomized trials 
evaluating anticoagulant prophylaxis in general surgery, Mismetti et al. (211), found no 
significant difference between LMWH and UFH in symptomatic VTE, major bleeding, 
transfusion and death. This finding is supported by the ENOXACAN study (212). The 
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ENOXACAN II study was conducted to examine the effect extended prophylaxis i.e. 21 
days, significantly reduced the incidence of DVT from 12% to 4.8% (p= 0.02).  
7.2 Thromboprophylaxis in hospitalized or bedridden cancer patients  
As the incidence of VTE in cancer patients who require hospitalization is very high, 
therefore they would benefit from primary anticoagulant prophylaxis. However, it is likely 
that the absolute and relative benefit of primary thromboprophylaxis will vary greatly 
amongst different patient groups because of the heterogeneity of cancer patient. It appears 
that the greatest potential impact of primary prophylaxis would be in patients initially 
diagnosed with advanced disease particularly those who are candidates for chemotherapy.  
Another subgroup of patients who may warrant primary thromboprophylaxis are patients 
initially diagnosed with local, or regional-stage cancer who progress and develop metastatic 
cancer or when they are admitted to hospital with an acute illness. Those patients should 
always be considered for primary pharmacological as well as mechanical 
thromboprophylaxis. Although none of the clinical studies evaluated a cancer-specific 
population, consensus statements and guidelines unanimously support the use of 
prophylaxis in cancer patients admitted to hospitals. 
7.3 Thromboprophylaxis in ambulatory cancer patients 
Much less is known about prevention of VTE in ambulatory cancer patients. The incidence 
of symptomatic VTE observed in ambulatory patients with advanced or metastatic 
malignancies in a recent clinical trial of 3% is considered low (26). Multiple recent studies 
have evaluated the potential benefit of thromboprophylaxis in ambulatory patients selected 
on the basis of one or two risk factors but have been unable to definitively identify patients 
who would benefit from prophylaxis  
In the double-blind study by Levine et al (213) evaluated the anticoagulant effect of very 
low-dose warfarin (INR1.3-1.9) in Stage IV breast cancer while they were receiving 
chemotherapy. However, more recent trials have failed to confirm the benefit of primary 
prophylaxis in the ambulatory setting.   
In summary, routine anticoagulant prophylaxis in medical oncology patients is not 
practiced because (a) the incidence of symptomatic VTE observed in ambulatory patients 
with advanced or metastatic malignancies is considered low. (b), the risk of bleeding 
remains a significant concern in most patients with cancer. (c) extended periods of primary 
prevention with an anticoagulant can be unattractive to most patients with cancer and (d) 
the optimal period of prophylaxis has not been identified.  
One established high-risk group in the ambulatory setting is multiple myeloma patients 
receiving combination therapy. All newly diagnosed patients treated with 
thalidomide/lenalidomide- containing regimens should receive thromboprophylaxis as 
detailed in chapter 5. 
7.4 Primary VTE prophylaxis in palliative care settings 
Sarah Mclean and James S O’Donnell (214) published a qualitative systemic review that 
covered the period (1960-2010) on this important aspect of management of cancer patients 
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(Palliative Medicine June 2010).  The authors pointed that primary thromboprophylaxis with 
LMWH is under utilized in the palliative setting although it is supported by level 1A 
evidence.  The authors stated that studies examined practice in specialist patient care units 
and attitude held by a total of 32 palliative care physicians and 198 patients for 
thromboprophylaxis revealed that patient perception of LMWH is based on physician’s 
concern regarding the negative impact on quality life and lack of evidence to support such 
practice.  The authors concluded that LMWH prophylaxis in palliative patients with 
previous good performance status needs further studies. 
7.5 Guidelines for VTE prophylaxis in cancer patients 
The recommendation of the American College of Chest Physicians (ACCP) guidelines on 
prevention of VTE recommends prophylaxis for acutely ill hospitalized medical/surgical 
patients with cancer (215). However, the compliance of oncologists with the 
recommendations remains low (216) and this may be due to lack of awareness or unfounded 
fear of bleeding within the oncology community.  Institution-based VTE prophylaxis 
guidelines with risk for VTE stratification followed by effective monitoring and auditing 
policy by the institution and sustained awareness campaigns could have a significant 
positive impact.  
The Guidelines 
The reader is referred to the following rich evidence-based guidelines: 
1. ACCP guidelines is an evidence-based on antithrombotic and thrombolytic therapy 
covering both prevention and treatment with selected issues related to cancer patients 
(http://www.chestnet.org/accp/) 
2. National Comprehensive Cancer Network (NCCN), a non-profit, alliance of 20 leading 
National Cancer Institute-designated Cancer Centers.  The NCCN develops and 
disseminates clinical practice guidelines in oncology.  The latest version of 
recommendations on VTE management can be found on-line at 
nccn.org/professionals/physicians_gls/PDF/vte.pdf. 
3. Italian Guidelines on Management of VTE in patients with cancer published on-line by 
the Italian Association of Medical Oncologists for Italian oncologists.  The guideline 
covers different aspects of VTE and cancer (a) VTE associated with occult malignancies 
(b) prophylaxis in cancer surgery, during chemotherapy, during hormonal therapy (c) 
VTE prophylaxis of VTE associated central venous catheters (d) treatment of VTE in 
cancer patients (e) anticoagulation and prognosis of cancer.  The Italian 
recommendations are updated annually. 
4. The American Society of Clinical Oncology Guidelines published its latest 
recommendations for VTE prophylaxis and treatment in patients with cancer in Dec 
2007, JCD volume 25, No. 34 (5490-5505).  Our reader is encouraged to refer to this 
informative and comprehensive document.  The ASCO recommendations are depicted 
in a user-friendly practical approach in a format of practical questions. 
1. Should hospitalized patients with cancer receive anticoagulation for VTE 
prophylaxis? 
2. Should ambulatory patients with cancer receive anticoagulation for VTE during 
systematic chemotherapy? 
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3. Should patients with cancer undergoing surgery receive preoperative VTE 
prophylaxis? 
4.  What is the best treatment for patients with cancer with established VTE to 
prevent recurrent VTE? 
5. Should patients with cancer receive anticoagulants in the absence of established 
VTE to improve survival? 
8. Consequences of cancer-associated thrombosis 
As depicted above in this chapter, the implications of diagnosis of VTE in a patient with 
cancer are many:  
a. Mortality:  cancer diagnosed at the same as or within a year of an episode of VTE is 
associated with 3-fold increase in mortality at one year.  Moreover, the mortality rate in 
hospitalized cancer patients is higher when they develop VTE.  For ambulatory cancer 
patients, initiating treatment with chemotherapy, VTE and arterial thrombosis has been 
reported to account for 9% of death. The risk of dying from fatal PE in cancer patient 
undergoing surgery is 3-fold higher than similar surgery in non-cancer patients.   
b. Bleeding complications: cancer patients with VTE and treated with anticoagulants are at 
two-fold greater risk of bleeding complications than patients with VTE but no cancer.  
c. Negative impact on healthcare resources:  in a retrospective study Etting LS et al (Arch Int 
Med 2008) reported that the average cost of hospitalization for the index DVT episode in 
cancer patients in USA was $20065 in 2002 and the attributable hospital stay was 11 days. 
d. Recurrence rate of VTE in a patient with cancer is 3-fold more frequently than in 
patients without cancer.  Prandoni et al (32) performed a prospective cohort study of 
consecutive patients with incident VTE and compared the incidence of recurrence and 
bleeding for those with and without cancer at the time of VTE. Patients were given 
heparin followed by warfarin. The 12-month cumulative incidence of recurrent VTE in 
the group with cancer was 20.7% (95% CI 15.6–25.8%) vs. 6.8% (95% CI 3.9–9.7%) in 
those without malignancy. The rate of recurrence was directly associated with tumor 
burden as prospectively assessed by the investigators. This study also confirmed that 
the risk of major bleeding was also higher for patients with extensive cancer on 
warfarin anticoagulation. Compared to patients without cancer, patients with cancer 
have a higher risk of thrombosis and recurrent thrombosis. Recent evidence from well-
conducted clinical trials shows that cancer patients may benefit from a longer duration 
of prophylaxis after surgery and that treatment with long-term LMWH is more effective 
than conventional oral anticoagulant therapy. Randomized studies have shown that 
prolonged (6 months) treatment with LMWH results in both lower VTE recurrence rates 
and less bleeding. Thus, LMWH is the therapy of choice for treatment of VTE in 
patients with cancer. However, the optimal duration of therapy for patients with active 
cancer has not been determined. 
e. Post-Thrombotic Syndrome 
Available data on the incidence of post-thrombotic syndrome in patients with cancer is 
scarce.  However, approximately 30% of patients with DVT subsequently develop this 
chronic, frequently disabling condition within 5 years of the event.  Of those, 8.1% will have 
severe post-thrombotic manifestations (Prandoni et al, 1997b) (8). It is expected that the 
incidence of the syndrome in cancer patients would be higher in view of adverse patient and 
www.intechopen.com
 
Venous Thromboembolism in Cancer Patients 
 
99 
treatment related factors.  Symptoms of post-thrombotic syndrome include debilitating leg 
pain, swelling, and fibrosis. Severe manifestations may result in debilitating leg ulceration, 
mobility problems, and the need for long-term nursing care. 
f. Pulmonary Hypertension 
Pulmonary hypertension is a life-threatening condition associated with fatigue, chest pain, 
peripheral swelling, and increased mortality. Recent studies suggest that 4–5% of patients 
develop pulmonary hypertension within years after symptomatic PE, Pengo et al, 2004 (216).  
9. Treatment of VTE 
Several studies have addressed treatment of VTE in patients with cancer:   
a. The CLOT (Comparison of Low-Molecular-Weight Heparin Versus Oral Anticoagulant 
Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with 
Cancer, N Engl J Med. 2003) study, which compared dalteparin with vitamin K 
antagonist (VKA) therapy, is the largest randomized trial of VTE treatment in patients 
with cancer (n = 672) (183).  This study reported a 52% RRR in the incidence of recurrent 
VTE in favor of dalteparin during the 6-month study period. 
b. Three additional studies assessed the use of LMWH for extended VTE treatment in 
patients with cancer. The CANTHANOX (Secondary Prevention Trial of Venous 
Thrombosis with Enoxaparin) study compared 3 months of warfarin therapy with 3 
months of enoxaparin therapy in patients with malignancy and proximal DVT or PE 
(218). Because of slow recruitment, the study was terminated prematurely.  At 3 
months, seven patients in the enoxaparin group had recurrent VTE or major bleeding 
(the combined primary end point) versus 15 patients in the warfarin group (P = 0.09). 
Most of the primary outcomes were due to major bleeding (five patients in the 
enoxaparin group versus 12 in the warfarin group). In the warfarin group, six of the 
patients died of major bleeding, and at the 6-month follow-up, 31% of patients in the 
enoxaparin group had died, compared with 38.7% of patients in the warfarin group (P = 
0.25). The findings of this limited study suggest that warfarin may be associated with a 
higher risk of bleeding than LMWH when used as long-term VTE treatment in patients 
with cancer (218).  
c. The three-arm ONCENOX (Secondary Prevention Trial of Venous Thrombosis with 
Enoxaparin) study included 101 patients with cancer and VTE. Because of the small 
number of patients enrolled, no differences between the enoxaparin and warfarin 
groups were observed with regard to the incidence of recurrent VTE, major bleeding, or 
death (219).  
d. The LITE (Long-Term Innohep Treatment Evaluation) study found tinzaparin to be 
more efficacious than warfarin in 200 patients with cancer (220). Tinzaparin treatment 
reduced the rate of recurrent VTE by ~50%; however, the difference was not statistically 
significant at the end of the 3-month treatment period. There were no differences in 
bleeding rates between the two groups. 
Compared with warfarin, LMWHs generally reduce the overall risk of recurrent VTE when 
used for the extended treatment of VTE, a finding confirmed by a recently published 
Cochrane systematic review (221). Furthermore, LMWHs do not increase major bleeding 
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rates and appear to be as safe as VKAs. These findings, like those seen in the prevention 
trials, appear to be related to the dose and the duration of therapy. 
The standard treatment for acute VTE is anticoagulant therapy. For initial therapy, 
subcutaneous (SC) LMWH is as effective and safe as intravenous UFH (28, 29). LMWHs are 
administered once or twice daily by SC injection, have weight-adjusted dosing and do not 
usually require laboratory monitoring. These advantages over UFH allow LMWHs to be 
given on an outpatient basis and reduce the need for hospitalization. 
Duration of therapy: Duration of anticoagulant therapy has not been addressed in cancer 
patients. Based on the accepted concept that the risk of recurrent thrombosis is increased in 
the presence of any ongoing risk factor, it is generally recommended that patients with 
metastases continue with ‘‘indefinite’’ therapy because metastatic malignancy is a persistent 
risk factor. In those without metastases, anticoagulant treatment is recommended for as long 
as the cancer is ‘‘active’’ and while the patient is receiving antitumor therapy. 
Secondary prophylaxis: Oral anticoagulant therapy with a vitamin K antagonist can be 
started on the same day as heparin therapy to begin secondary prophylaxis. To effectively 
reduce recurrent VTE without excessive bleeding, the dose of oral anticoagulants must be 
adjusted to maintain the INR within a therapeutic range of 2.0 to 3.0. This usually requires 
twice weekly blood work for the first 1 to 2 weeks until a stable dose is identified. Using this 
regimen, the annual incidence of recurrent VTE in patients without cancer is approximately 
8%, whereas the risk of recurrence is two- to threefold higher in patients with cancer.  
The higher failure rate in cancer patients may reflect the greater difficulty in maintaining 
therapeutic INR levels because of multiple drug interactions, gastrointestinal upset, vitamin 
K deficiency, liver dysfunction and poor venous access. Also, temporary discontinuation of 
anticoagulant therapy is often necessary during periods of thrombocytopenia and to 
accommodate invasive procedures. Such interruptions can cause lengthy periods of 
inadequate anticoagulation because vitamin K antagonists have a delayed onset of action 
and a prolonged period of clearance. Furthermore, warfarin failure, i.e. recurrent VTE 
despite maintaining therapeutic INR levels, is not uncommonly reported in cancer patients 
on oral anticoagulant therapy. 
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